Literature DB >> 15475873

Cognitive factors in schizophrenia: causes, impact, and treatment.

Herbert Y Meltzer1.   

Abstract

Greater attention has been given to the cognitive dimension in schizophrenia in recent years. This has resulted from increased recognition that cognitive impairment and negative symptoms of the disease have a greater impact on quality of life (QOL) compared to positive symptoms. Successful treatment of positive symptoms in patients with schizophrenia has not been shown to robustly translate into improvements in employment status or social relationships, while cognitive improvements are strongly associated with these important aspects of QOL and independence. These findings are based on extensive testing with standard cognitive tests for measuring executive function, verbal learning and memory, word recall, verbal working memory, spatial working memory, attention, and vigilance. Verbal learning and executive function, in particular, have been found to be valid predictors of employment success independent of the degree of severity of positive symptoms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475873     DOI: 10.1017/s1092852900025098

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  11 in total

1.  The RSM-scale: a pilot study on a new specific scale for self- and observer-rated quality of life in patients with schizophrenia.

Authors:  M Riedel; I Spellmann; R Schennach-Wolff; M Obermeier; R Musil
Journal:  Qual Life Res       Date:  2010-10-05       Impact factor: 4.147

Review 2.  Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.

Authors:  Kazuto Oya; Yuki Matsuda; Shinji Matsunaga; Taro Kishi; Nakao Iwata
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-25       Impact factor: 5.270

Review 3.  Promise and pitfalls of animal models of schizophrenia.

Authors:  David Feifel; Paul D Shilling
Journal:  Curr Psychiatry Rep       Date:  2010-08       Impact factor: 5.285

4.  Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics.

Authors:  Ilja Spellmann; Norbert Müller; Richard Musil; Peter Zill; Anette Douhet; Sandra Dehning; Anja Cerovecki; Brigitta Bondy; Hans-Jürgen Möller; Michael Riedel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03-17       Impact factor: 5.270

5.  Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.

Authors:  Michael Riedel; Norbert Müller; Ilja Spellmann; Rolf R Engel; Richard Musil; Rosamaria Valdevit; Sandra Dehning; Anette Douhet; Anja Cerovecki; Martin Strassnig; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-10       Impact factor: 5.270

6.  Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Authors:  Michael Riedel; Ilja Spellmann; Martin Strassnig; Anette Douhet; Sandra Dehning; Markus Opgen-Rhein; Rosamaria Valdevit; Rolf R Engel; Nikolaus Kleindienst; Norbert Müller; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-07-14       Impact factor: 5.270

7.  Synthesis and evaluation of a series of 2-substituted-5-thiopropylpiperazine (piperidine)-1,3,4-oxadiazoles derivatives as atypical antipsychotics.

Authors:  Yin Chen; Xiangqing Xu; Xin Liu; Minquan Yu; Bi-Feng Liu; Guisen Zhang
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

Review 8.  Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases.

Authors:  Samuele Maramai; Sandra Gemma; Simone Brogi; Giuseppe Campiani; Stefania Butini; Holger Stark; Margherita Brindisi
Journal:  Front Neurosci       Date:  2016-10-05       Impact factor: 4.677

9.  Metabolic changes in schizophrenia and human brain evolution.

Authors:  Philipp Khaitovich; Helen E Lockstone; Matthew T Wayland; Tsz M Tsang; Samantha D Jayatilaka; Arfu J Guo; Jie Zhou; Mehmet Somel; Laura W Harris; Elaine Holmes; Svante Pääbo; Sabine Bahn
Journal:  Genome Biol       Date:  2008-08-05       Impact factor: 13.583

10.  Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone.

Authors:  Hikaru Hori; Kenji Yamada; Dan Kamada; Yuka Shibata; Asuka Katsuki; Reiji Yoshimura; Jun Nakamura
Journal:  Neuropsychiatr Dis Treat       Date:  2014-03-26       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.